All In Biotech

Drug Trial Radar · NCT04374136

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 119 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

119

Actual

Start

Jul 23, 2020

Primary completion

Sep 1, 2025

Study completion Jan 6, 2026

Sponsor

Lead sponsor
Alector Inc.Industry
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
May 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

Conditions

  • Frontotemporal Dementia

Interventions

  • Part 1 Blinded - AL001Drug

    Administered via intravenous (IV) infusion

  • Part 1 Blinded - PlaceboDrug

    Administered via intravenous (IV) infusion

  • Part 2 (OLE Treatment) - AL001Drug

    Administered via intravenous (IV) infusion

  • Part 2 (OLE Treatment) - Placebo Switched to AL001Drug

    Administered via intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic PatientsTime frame: Through study completion, on average up to 96 weeks
  2. Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic PatientsTime frame: Baseline to 96 weeks
  3. Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the StudyTime frame: 96 weeks

Locations

44 sites in 16 countries. Site status is shown where the registry gives one.

  • Dignity Health

    Phoenix, Arizona

  • University of California San Diego

    La Jolla, California

  • University of Colorado

    Aurora, Colorado

  • Emory University

    Atlanta, Georgia

  • Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • University of Kansas Alzheimer's Disease Center

    Fairway, Kansas

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Mayo Comprehensive Cancer Center - PPDS

    Rochester, Minnesota

  • Irving Institute for Clinical and Translational Research

    New York, New York

  • University Of Cincinnati Gardner Neuroscience institute

    Cincinnati, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Houston Methodist Institute for Academic Medicine

    Houston, Texas

  • Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia

    Buenos Aires, Argentina

  • Box Hill Hospital

    Box Hill, Australia

  • The Queen Elizabeth Hospital

    Woodville, Australia

  • UZ Leuven

    Leuven, Vlaams Brabant, Belgium

  • The University of Western Ontario

    London, Canada

  • Sunnybrook Research Institute - University of Toronto

    Toronto, Canada

  • CHU de Bordeaux

    Bordeaux, France

  • CHRU Lille

    Lille, France

  • Groupe Hospitalier Pitié Salpétrière

    Paris, France

  • Uniklinik Köln

    Cologne, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Eginitio University General Hospital of Athens - 1st University Neurology Clinic

    Athens, Attica, Greece

  • University General Hospital of Alexandroupolis - Department of Neurology

    Alexandroupoli, Evros, Greece

  • Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara

    Baggiovara, Italy

  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia

    Brescia, Italy

  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli

    Brescia, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta

    Milan, Italy

  • PIA Fondazione Panico

    Tricase, Italy

  • Erasmus MC

    Rotterdam, Netherlands

  • Centro Hospitalar E Universitário de Coimbra EPE

    Coimbra, Portugal

  • Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria

    Lisbon, Portugal

  • Hospital CUF Descobertas

    Lisbon, Portugal

  • Centro Hospitalar do Porto - Hospital de Santo António

    Porto, Porto District, Portugal

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Spain

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.